Early Transcriptional Signature in Dendritic Cells and the Induction of Protective T Cell Responses Upon Immunization With VLPs Containing TLR Ligands

Early Transcriptional Signature in Dendritic Cells and the Induction of Protective T Cell Responses Upon Immunization With VLPs Containing TLR Ligands—A Role for CCL2

Published:2019-08-02 Issue: Volume:10 Page:
ISSN:1664-3224
Container-title:Frontiers in Immunology
language:
Short-container-title:Front. Immunol.

Author:

Gomes Ariane C.,Mohsen Mona O.,Mueller Julius E.,Leoratti Fabiana M. S.,Cabral-Miranda Gustavo,Bachmann Martin F.

Funder

Conselho Nacional de Desenvolvimento Científico e Tecnológico

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Publisher

Frontiers Media SA

Subject

Immunology,Immunology and Allergy

Reference34 articles.

1. Nano-particle vaccination combined with TLR-7 and−9 ligands triggers memory and effector CD8+ T-cell responses in melanoma patients;Goldinger;Eur J Immunol.,2012

2. Nanoparticle drug delivery systems designed to improve cancer vaccines and immunotherapy;Fan;Vaccines,2015

3. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy;Kranz;Nature.,2016

4. Crossroads Between Innate and Adaptive Immunity IV

5. Innate signaling regulates cross-priming at the level of DC licensing and not antigen presentation;Keller;Eur J Immunol.,2010

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identifying Key Drivers of Efficient B Cell Responses: On the Role of T Help, Antigen-Organization, and Toll-like Receptor Stimulation for Generating a Neutralizing Anti-Dengue Virus Response;Vaccines;2024-06-14

2. Virus-like particles (VLPs)-based vaccines against COVID-19: Where do we stand amid the ongoing evolution of SARS-CoV-2?;Health Sciences Review;2023-12

3. Development of virus‐like particles‐based vaccines against coronaviruses;Biotechnology Progress;2022-08-19

4. Exploiting viral sensing mediated by Toll-like receptors to design innovative vaccines;npj Vaccines;2021-10-28

5. Virus‐like particles displaying recombinant Der p 1 zymogen to optimize IgG blocking antibody response;Allergy;2021-10-15